SUMMARY OF SAFETY AND EFFECTIVENESS DATA RELATING TO SUBSTANTIAL EQUIVALENCE

Proprietary Name:

Narkomed MRI-2 Anesthesia System

Classification Name:

Gas Machine, Anesthesia - 73 BSZ

Device Class:

Class II

Initial Distributor:

Draeger Medical, Inc. 3135 Quarry Road

Telford, Pennsylvania 18969 USA

Establishment Registration No.:

2517967

Predicate Device:

Narkomed MRI Anesthesia System - K001488

Device Description:

The Narkomed MRI-2 (NM-MRI-2) is a continuous flow gas anesthesia system.

Intended Use:

The NM-MRI-2 can be used for spontaneous, manually assisted or automatic ventilation, delivery of gases and anesthetic vapor, and monitoring oxygen concentration, breathing pressure and respiratory volume of patients during anesthesia. The NM-MRI-2 is intended for use with Dräger-Vapor® vaporizers. The NM-MRI-2 can be used in MRI scanner rooms with magnets up to 1.5 tesla.

Substantial Equivalence:

The Narkomed MRI-2 Anesthesia System is substantially equivalent to the currently distributed Narkomed MRI Anesthesia System. The NM-MRI-2 is identical to the NM-MRI except for the addition of a second vapor mount and exclusion system, a tracheal suction system and an aluminum writing tray.

Qualification of the NM-MRI-2 included hazard analysis and system level qualification. Image compatibility testing confirmed that the NM-MRI-2 does not negatively impact the diagnostic quality of images produced by the MRI machine or disturb the homogeneity of the main magnetic field.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JAN 2 2 2001

Mr. Michael A. Kelhart Draeger Medical, Inc. 3135 Quarry Road Telford, PA 18969

Re: K003579

Narkomed MRI-2 Anesthesia System

Regulatory Class: II (two)

Product Code: 73 BSZ
Dated: December 22, 2000
Received: December 26, 2000

Dear Mr. Kelhart:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Mr. Michael A. Kelhart

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

James E. Dillard III

Director

Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

				Page	<u> </u>	_ of _	1
10(k) Number (i	f known): _	K003579		***************************************			
Device Name:	Narkomed MI	RI-2 (NM-MRI-2	2) Anesthesia S	ystem			
ndications for U	se:						
The NM-MRI-2 of gases and ane espiratory volumed Trager-Vapor® of 1.5 tesla.	sthetic vapor	r, and monitoring ts during anesth	ng oxygen con nesia. The NM	centration, bread- I-MRI-2 is inte	athing pr nded for	essure a use with	na 1
PLEASE DO ! NEEDED)	NOT WRIT	E BELOW TI	HIS LINE – C	CONTINUE O	N ANO	THER P	AGE I
	Concurre	ence of CDRH,	Office of Dev	ice Evaluation	(ODE)		
Prescription Use (Per 21 CFR 80	e 1.109)	· · · · · · · · · · · · · · · · · · ·	OR	Over-7	The-Cour	nter-Use	
		Stept	ERU	odu			
	Di	vision of Cardiov	ascular & Resp	iratory Devices			

(Optional Format 1-2-96)